Pain - Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Pain - Identifying and
Commercializing First-in-Class Innovation
Single User License - 6995 Site User
License - 13990 Corporate User License -
20985 Publication Date - Jan 2015 Pages -
106 To know more details, email to
debora_at_reportstack.com
2
Summary

• The active pain pipeline is populated by 796
  products across all stages of development, which
  exhibit a highly diverse range of molecular
  targets. The Researchs analyses identified 122
  first-in-class programs in active development,
  constituting 13.6 of the pipeline and acting on
  65 first-in-class molecular targets, indicating a
  high degree of innovation. This is in stark
  contrast to the pain therapeutics market, which
  has been largely characterized by only
  incremental product innovation over the last
  decade, as most market segments continue to be
  dominated by long-established active
  pharmaceutical ingredients and the concomitant
  mechanisms of action. Moderate-to-severe pain
  continues to be dominated by opioids that are
  increasingly being reformulated to offer
  abuse-resistance, while mild pain is effectively
  treated with Non-Steroidal Anti-Inflammatory
  Drugs (NSAID).

3
Scope

• A brief introduction to pain, including the
  different subtypes of pain, pathophysiology, and
  overview of pharmacotherapy and treatment
  algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets
• Assessment of the licensing and co-development
  deal landscape for pain therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products

4
Key Benefits

• Understand the focal shifts in molecular targets
  in the pain therapeutics pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for pain,
  benchmarked against non-first-in-class targets.
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com